Literature DB >> 8162580

Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action.

L I Gold1, B Saxena, K R Mittal, M Marmor, S Goswami, L Nactigal, M Korc, R I Demopoulos.   

Abstract

Endometrial carcinoma is associated with antecedent simple and complex hyperplasia, and the endometrium is a target tissue for the action of cytokines and growth factors. Transforming growth factor (TGF)-beta s are potent cellular growth and differentiation regulatory factors. Therefore, we investigated the potential role for TGF-beta s in the normal proliferative endometrium and its possible involvement in the transition to complex hyperplasia and progression to endometrial carcinoma. The angiogenic and mitogenic growth factor, basic fibroblast growth factor, was used for comparison. Differential TGF-beta isoform-specific immunoreactivity was observed in the normal endometrium, which is composed of glandular and stromal cells. There was an increase in TGF-beta 3 but not TGF-beta 1 or TGF-beta 2 in the glandular epithelium from the proliferative to the secretory phase of the menstrual cycle. Immunostaining for TGF-beta 2 was more intense in the stroma than the glands. In contrast, TGF-beta 1 and TGF-beta 3 were near equal intensity in these two endometrial compartments, TGF-beta 3 being the most intense. The glandular epithelium demonstrated a statistically significant stepwise increase in the expression of all three TGF-beta s progressing from the normal proliferative endometrium to simple hyperplasia and on to complex hyperplasia. However, the stromal cells maintained approximately the same level of immunoreactivity for TGF-beta in all these samples. In comparing proliferative endometrium with complex hyperplasia, there was a 5.1-, 3.4-, and 2.6-fold increase in immunostaining in the glands for TGF-beta 1, TGF-beta 2, and TGF-beta 3, respectively (P < or = 0.001). There was no further increase in immunoreactivity with progression from preneoplastic complex hyperplasia to carcinoma. Immunoreactive basic fibroblast growth factor was slight in normal endometrium and simple hyperplasia. There was a 4.6- and 4.2-fold increase in immunostaining observed in complex hyperplasia compared with proliferative endometrium in the glandular (P < or = 0.0054) and stromal (P < or = 0.0053) cells, respectively, with no further increase in carcinoma. By in situ hybridization, an increase in mRNA for all TGF-beta isoforms paralleled TGF-beta immunoreactivity. However, in contrast to the increased immunostaining in the glands in complex hyperplasia, there was remarkably more mRNA in the stromal cell compartment. The discordant expression of mRNA and protein was only observed in the pathological endometrium since both were more highly expressed in the stromal cells in normal proliferative endometrium.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162580

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair.

Authors:  L I Gold; J J Sung; J W Siebert; M T Longaker
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

2.  Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.

Authors:  M J Pineda; Z Lu; D Cao; J J Kim
Journal:  Horm Cancer       Date:  2015-05-15       Impact factor: 3.869

3.  Differential Expression of TGF-β Isoforms in Human Kerationocytes by Narrow Band UVB.

Authors:  Moon Chul Jung; Min Kyung Shin; Kyung Kook Hong; Ki Heon Jeong; Nack In Kim
Journal:  Ann Dermatol       Date:  2008-09-30       Impact factor: 1.444

4.  Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer.

Authors:  Maya Gulubova; Irena Manolova; Julian Ananiev; Alexander Julianov; Yovcho Yovchev; Katya Peeva
Journal:  Int J Colorectal Dis       Date:  2010-02-18       Impact factor: 2.571

5.  Differential expression of TGF-beta isoforms during differentiation of HaCaT human keratinocyte cells: implication for the separate role in epidermal differentiation.

Authors:  Hang-Rae Cho; Seok-Beom Hong; Young Il Kim; Jin-Woo Lee; Nack-In Kim
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

6.  Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.

Authors:  P M Pollock; M G Gartside; L C Dejeza; M A Powell; M A Mallon; H Davies; M Mohammadi; P A Futreal; M R Stratton; J M Trent; P J Goodfellow
Journal:  Oncogene       Date:  2007-05-21       Impact factor: 9.867

7.  Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium.

Authors:  K L Bruner; W H Rodgers; L I Gold; M Korc; J T Hargrove; L M Matrisian; K G Osteen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

8.  Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor.

Authors:  J A Uría; M Balbín; J M López; J Alvarez; F Vizoso; M Takigawa; C López-Otín
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

9.  Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma.

Authors:  E Perlino; G Loverro; E Maiorano; T Giannini; A Cazzolla; A Napoli; M G Fiore; R Ricco; E Marra; L Selvaggi
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

10.  Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells.

Authors:  Xiaoping Luo; Jingxia Xu; Nasser Chegini
Journal:  Reprod Biol Endocrinol       Date:  2003-12-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.